No abstract

No abstract

The effect of orlistat, a nonabsorbed inhibitor of gastric and pancreatic lipases, was examined in patients with primary hyperlipidaemia (serum cholesterol > or = 6.2 mmol.l-1 and triglycerides < or = 5.0 mmol.l-1) not responsive to dietary change alone. In a multicentre, randomised, double-blind study, 103 men and 70 women received 30, 90, 180, or 360 mg or orlistat or placebo for 8 weeks. Total and low-density lipoprotein cholesterol levels were reduced by 4% and 5% with 30 mg orlistat, by 7% and 8% with 90 mg orlistat, by 7% and 7% with 180 mg orlistat and by 11% and 10% with 360 mg orlistat compared to placebo. High density lipoprotein cholesterol levels significantly decreased in the 360 mg orlistat group. Triglyceride levels significantly increased in the placebo group but not in the drug groups. Body weight decreased by 1.2 kg with 360 mg orlistat, despite a weight maintenance diet. Decreases in vitamin E and D levels occurred, although both vitamins remained within the normal range. Adverse effects from the gastrointestinal tract were frequent, but led to discontinuation of therapy in only seven patients. Orlistat is a new therapeutic drug for the treatment of hyperlipidaemia that may be particularly useful among overweight patients. Its potential place in therapy will await long-term studies. Vitamin supplementation should be considered during treatment.

Effects of recombinant porcine somatotropin (rpST) on growth, lean tissue growth, feed intake, feed conversion, lean tissue feed conversion, backfat thickness and lean percentage were examined in 96 growing pigs. The experiment used barrows and gilts from the genotypes Duroc, F1 (Dutch Yorkshire x Dutch Landrace) and Pietrain. Half the pigs received 14 mg rpST i.m. twice each week starting at 60 kg; others received a placebo. Pigs had ad libitum access to a diet containing 2,162 kcal net energy and 182 g crude protein per kilogram and were slaughtered at either 100 or 140 kg live weight. From 60 to 100 and from 100 to 140 kg, live weight responses to rpST averaged as follows: daily gain, +4.5 and +19.9%; feed intake, -4.4 and +3.5%; feed conversion, -8.4 and -13.9%; backfat thickness, -13.8 and -22.8%; lean percentage, +4.4 and +8.7%; lean tissue growth rate, +8.6 and +35.8%; and lean tissue feed conversion, -13.1 and -24.9%. No gender x rpST interaction was detected. However, a genotype x treatment interaction was significant for backfat thickness at both slaughter weights, showing a higher response to rpST in Duroc than in Pietrain and F1. Growth performance was improved more by rpST in F1 and Pietrain than in Duroc, especially at higher weights, but carcass traits were improved more by rpST in Duroc. The response to rpST in lean tissue growth rate from 60 to 100 kg was highest in fatter animals (Duroc, barrows), whereas from 100 to 140 kg, response in lean tissue growth rate to rpST was highest in leaner animals (Pietrain, F1, gilts).

Background: Curcumin is an active constituent of Curcuma longa, which belongs to Zingiberaceae family. It is derived from the Rhizome of a perennial plant having molecular formula C21H20O6 and chemically it is (1, 7- bis (4- hydroxy - 3 methoxyphenyl) -1, 6 - heptadine - 3, 5 - diene), also known as diferuloylmethane. Curcumin has been extensively used as a herbal constituent for curing several diseases and is scientifically proven to show major effects as an anti-inflammatory agent. Objective: Inflammation is an important factor for numerous diseases including diabetes neuropathy, cancer, asthma, arthritis, and other diseases. Prophylaxis of inflammatory diseases through synthetic medications tends to have major toxicity and side effects on a large number of population. The foremost aim of this review paper is to assess the natural anti-inflammatory effect of curcumin, source, and mechanism of action, potential therapeutic effect and models associated. Additionally, this paper aims to scrutinize inflammation, sources of reactive oxygen species, and pathways of reactive oxygen species generation and potential side effects of curcumin. Methods: Selection of data has been done by studying the combination of research and review papers from different databases like PubMed, Medline and Web of science from the year 1985- 2018 by using search keywords like “curcumin”, “anti-inflammatory”, “ROS”, “Curcuma longa”, “medicinal uses of curcumin”, “assessing parameters”, “inflammation”, “anti-oxidant” Results: On the basis of our interpretation, we have concluded that curcumin has potential therapeutic effects in different inflammatory diseases, it inhibits the inflammatory mediators, oxidation processes, and oxidative stress and has no severe toxicity on animals and humans. Conclusion: Oxidative stress is a major cause of inflammation and curcumin has a good potential for blocking it. Curcumin is also easily accessible herbal source and should be consumed in the form of food, antioxidant, anti-inflammatory agents and further observation should be done on its therapeutic parameters, risk factors, and toxicity studies and oral viability.